2022--provirex--hamburg-researchers-want-to-be-able-to-cure-hiv-soon---magazine--healty-and-sport-news · Working & Authentic

In 2022, Hamburg emerged as a primary hub for curative HIV research following significant investment in , a biotech startup utilizing "designer recombinase" technology. Unlike traditional antiretroviral therapy (ART) which only suppresses viral replication, the Brec1 recombinase acts as a molecular scalpel to precisely excise integrated HIV-1 DNA from the host genome. This paper details the 2022 expansion of Hamburg’s "Therapy Hub," the underlying Brec1 technology, and the transition toward Phase Ib/IIa clinical trials. 1. The Challenge: Beyond Viral Suppression

In October 2022, PROVIREX announced a major expansion in Hamburg’s . In 2022, Hamburg emerged as a primary hub

Unlike CRISPR-Cas9, which creates double-strand breaks and relies on error-prone cellular repair, Brec1 performs a concerted "cut and paste" action that is inherently error-free. Building upon the research conducted by and the

Building upon the research conducted by and the University Medical Center Hamburg-Eppendorf (UKE) , this paper outlines the scientific and strategic progress made toward a functional HIV cure as of late 2022. Abstract " the underlying Brec1 technology